Co-infection with SARS-CoV-2 and influenza A virus
Shuhei Azekawa,
Ho Namkoong,
Keiko Mitamura,
Yoshihiro Kawaoka,
Fumitake Saito
Affiliations
Shuhei Azekawa
Department of Pulmonary Medicine, Eiju General Hospital, Tokyo, Japan
Ho Namkoong
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA; Japan Society for the Promotion of Science, Tokyo, Japan; Corresponding author at: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Keiko Mitamura
Division of Infection Control, Eiju General Hospital, Tokyo, Japan
Yoshihiro Kawaoka
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA
Fumitake Saito
Department of Pulmonary Medicine, Eiju General Hospital, Tokyo, Japan; Division of Infection Control, Eiju General Hospital, Tokyo, Japan
Coronavirus Disease 2019 (COVID-19) infection, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is spreading globally and poses a major public health threat. We reported a case of influenza A virus and SARS-CoV-2 co-infection. As the number of COVID-19 cases increase, it will be necessary to comprehensively evaluate imaging and other clinical findings as well as consider co-infection with other respiratory viruses.
